Summary
To test the hypothesis that the initial response to corticosteroid treatment makes it possible to predict the further course of patients with polymyalgia rheumatica (PMR), 20 patients with PMR were prospectively given a therapeutic challenge with 15 mg of prednisolone (PDN) per day. The erythrocyte sedimentation rate (ESR), the fibrinogen and the C-reactive protein (CRP) were measured before and after 7 days of therapy. At the end of the challenge, the CRP had normalized in 11 patients (Group I), whereas it had remained elevated in 9 (Group II). The dose of PDN was thereafter tapered according to a strict and standard schedule integrating clinical and laboratory parameters, and was used as the index of disease control. The statistical analysis was made using a generalized linear model.
Follow-up ranged from 8 to 60 months with a median of 38 months. With the PDN dose as the end point, Group I showed a significantly better course than Group II (p=0.014). There were fewer adverse events due to corticosteroid treatment in Group I (3/11) compared to Group II (7/9). We conclude that the CRP initial response to the corticosteroid treatment is a prognostic factor in patients with PMR. Larger studies are needed to confirm these preliminary results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Delecoeuillerie, G., Joly, P., Cohen de Lara, A., Paolaggi, J.B. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year surgery of 210 patients). Ann Rheum Dis 1988, 47, 733–739.
Ayoub, W.T., Franklin, C.M., Torretti, D. Polymyalgia rheumatica. Duration of therapy and outcome. Am J Med 1985, 79, 309–315.
Kyle, V., Hazleman, B.L. Treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). II. The relationship between steroid dose and steroid-associated side effects. Ann Rheum Dis 1989, 48, 662–666.
Kyle, V., Hazleman, B.L. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. BMJ 1990, 300, 344–345.
Kyle, V. Treatment of polymyalgia rheumatica/giant cell arteritis. Baillères Clin Rheumatol 1991, 5, 485–491.
Vilaseca, J., Gonzales, A., Cid, M.C., Lopez-Vivancos, J., Ortega, A. Clinical usefulness of temporal artery biopsy. Ann Rheum Dis 1987, 46, 282–285.
Euller-Ziegler, L., Ziegler, G., Gristot, C., Leloire, P., Thomas, Y. Etude évolutive de la pseudopolyarthrite rhizomélique. A propos de 97 cas. Rev Rhum 1984, 51, 421–423.
Kyle, V., Cawston, T.E., Hazelman, B.L. Erythrocyte sedimentation rate and c-reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis 1989, 48, 667–671.
Boyd, R.V., Hoffbrand, B.I. Erythrocyte sedimentation rate in elderly hospital in-patients. Br Med J 1966, 2, 901902.
Hayes, G.S., Stinson, I.N. Erythrocyte sedimentation rate and age. Arch Ophtalmol 1976, 94, 939–940.
Mallya, R.K., Hind, C.R.K., Berry, H., Pepys, M.B. Serum C-Reactive protein in polymyalgia rheumatica. Arhritis Rheum 1985, 28, 383–387.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schreiber, S., Buyse, M. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. Clin Rheumatol 14, 315–318 (1995). https://doi.org/10.1007/BF02208345
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02208345